Endologix Inc. (ELGX)

2.86
0.02 0.69
NASDAQ : Health Technology
Prev Close 2.88
Open 2.91
Day Low/High 2.85 / 3.00
52 Wk Low/High 2.28 / 10.40
Volume 7.40K
Avg Volume 200.70K
Exchange NASDAQ
Shares Outstanding 17.94M
Market Cap 51.31M
EPS -9.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Figure 1. Freedom From Aneurysm-Related Complications (ARC) In The LEOPARD Trial (Graphic: Business Wire)

Figure 1. Freedom From Aneurysm-Related Complications (ARC) In The LEOPARD Trial (Graphic: Business Wire)

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced a response to the U.

Endologix, Inc. To Announce Third Quarter 2019 Financial Results On November 6, 2019

Endologix, Inc. To Announce Third Quarter 2019 Financial Results On November 6, 2019

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2019 after the market close on Wednesday, November 6, 2019.

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees (together, the "Awardees").

Endologix Announces Exclusive Distributor Agreement With Boston Scientific For The Chinese Market

Endologix Announces Exclusive Distributor Agreement With Boston Scientific For The Chinese Market

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China.

Endologix Receives IDE Approval For The Nellix Chimney EndoVascular Aneurysm Sealing Protocol

Endologix Receives IDE Approval For The Nellix Chimney EndoVascular Aneurysm Sealing Protocol

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to...

Endologix Reports Second Quarter 2019 Financial Results

Endologix Reports Second Quarter 2019 Financial Results

Endologix, Inc. (the "Company") (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019.

Endologix, Inc. To Announce Second Quarter 2019 Financial Results On August 8, 2019

Endologix, Inc. To Announce Second Quarter 2019 Financial Results On August 8, 2019

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2019 after the market close on Thursday, August 8, 2019.

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the "Awardees").

Endologix, Inc. To Present At The BMO Prescriptions For Success Healthcare Conference

Endologix, Inc. To Present At The BMO Prescriptions For Success Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the 2019 BMO Prescriptions...

Endologix Announces Reinstatement Of CE Mark For Its Nellix EndoVascular Aneurysm Sealing System

Endologix Announces Reinstatement Of CE Mark For Its Nellix EndoVascular Aneurysm Sealing System

Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been reinstated...

Endologix Reports First Quarter 2019 Financial Results

Endologix Reports First Quarter 2019 Financial Results

Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2019.

Endologix, Inc. To Announce First Quarter 2019 Financial Results On May 2, 2019

Endologix, Inc. To Announce First Quarter 2019 Financial Results On May 2, 2019

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019.

Endologix Announces Equity Financing Of $52 Million And Debt Restructuring Addressing 2020 Maturities And Financial Covenants

Endologix Announces Equity Financing Of $52 Million And Debt Restructuring Addressing 2020 Maturities And Financial Covenants

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into a definitive agreement to raise approximately $52 million gross cash proceeds through the...

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to nine newly hired employees (the "Awardees").

Endologix Announces Approval Of Reverse Stock Split

Endologix Announces Approval Of Reverse Stock Split

Endologix, Inc. (the "Company") (NASDAQ: ELGX) previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation to...

Endologix Reports Fourth Quarter And Fiscal Year 2018 Financial Results

Endologix Reports Fourth Quarter And Fiscal Year 2018 Financial Results

Endologix, Inc. (the "Company") (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018.

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to eight newly hired employees (the "Awardees").

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2018 Financial Results On February 25, 2019

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2018 Financial Results On February 25, 2019

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2018 after the market close on Monday, February 25, 2019.

Endologix Provides Update On Previously Announced Voluntary Nellix System Recall

Endologix Provides Update On Previously Announced Voluntary Nellix System Recall

Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been suspended...

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to a newly hired executive (the "Awardee").

Endologix Appoints John D. Zehren As Chief Commercial Officer

Endologix Appoints John D. Zehren As Chief Commercial Officer

Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D.

Endologix Announces Fourth Quarter And Full-Year 2018 Preliminary Financial Results And Provides 2019 Financial Guidance

Endologix Announces Fourth Quarter And Full-Year 2018 Preliminary Financial Results And Provides 2019 Financial Guidance

Endologix, Inc. (the "Company") (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately...

Endologix Takes Decisive Action To Optimize Patient Outcomes By Ensuring Nellix System Used Only Within Current Indications

Endologix Takes Decisive Action To Optimize Patient Outcomes By Ensuring Nellix System Used Only Within Current Indications

Endologix® Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today that in order to ensure optimal outcomes for patients, unrestricted sales and use of the Nellix System...

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the 37 th Annual J.

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the "Awardees").

Endologix Honors Innovators Of Aortic Therapy At VEITHsymposium

Endologix Honors Innovators Of Aortic Therapy At VEITHsymposium

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45 th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons...

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the "Awardees").

Endologix Reports Third Quarter 2018 Financial Results

Endologix Reports Third Quarter 2018 Financial Results

Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2018.

TheStreet Quant Rating: D- (Sell)